Core Viewpoint - TC BioPharm confirms its compliance with all Nasdaq listing requirements and refutes rumors of potential delisting from the exchange [1][2] Company Compliance and Response - The company has stated that it is not in danger of being delisted from Nasdaq and remains compliant with all listing requirements [1][2] - TC BioPharm plans to take action against false claims that aim to create negative market dynamics [2] Company Overview - TC BioPharm is a clinical-stage biotechnology company focused on developing gamma-delta T cell therapies for cancer treatment, with human efficacy data in acute myeloid leukemia [4] - The company is a leader in this field and has conducted phase II/pivotal clinical studies in oncology [4] - TC BioPharm is currently conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for acute myeloid leukemia using proprietary CryoTC technology [4]
TCBP Responds to False Social Media Claim